ArticleThe World Allergy Organization journal2026
Increased glucose transporter 1 contributes to epithelial barrier dysfunction in allergic rhinitis.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Glucose Transporters: Structure, Trafficking, Physiology, and Disease Relevance.Current issues in molecular biology · 2026Review
- Glioblastoma Stem Cells and Tumour Microenvironment: Interactions Across Hypoxia, Vasculature and Immune Modulation.International journal of molecular sciences · 2026Review
- The role of calcium homeostasis dysregulation in allergic rhinitis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelial barrier impairment is a characteristic pathological hallmark of allergic rhinitis (AR), yet the mechanisms contributing to this dysfunction remain incompletely understood. Our aim is to assess the impact of glucose transporter 1 (GLUT1) on epithelial barrier function in AR. Methods: We performed proteomics analysis on nasal mucosa from AR patients and healthy controls (HCs) to identify differential proteins, which were validated using immunofluorescence, western blotting, and RT-qPCR. Nasal epithelial cells from HCs were isolated to evaluate house dust mite (HDM)-induced changes in GLUT1 expression and regulatory mechanisms. An AR mouse model was constructed to examine the effects of GLUT1 inhibition on nasal inflammation and barrier function. Results: Tissue proteomics analysis revealed a distinct protein expression profile in AR patients compared with HCs, with GLUT1 identified as the most upregulated protein. Cohort validation demonstrated significantly elevated GLUT1 expression in the AR group, predominantly localized in epithelial cells. Moreover, GLUT1 mRNA levels showed a positive correlation with visual analogue scales and total nasal symptom scores, and a negative correlation with tissue ZO-1 and occludin expressions. In vitro studies indicated that HDM stimulation enhanced GLUT1 expression and reduced ZO-1 and occludin levels in nasal epithelial cells in a dose-dependent manner. Treatment with a GLUT1 inhibitor effectively restored ZO-1 and occludin expressions. Animal model experiments further confirmed that GLUT1 inhibition alleviated nasal inflammation and improved mucosal barrier function. Conclusion: AR displays a distinct tissue-specific protein expression profile, with enhanced GLUT1 levels associated with disease severity and epithelial barrier dysfunction. Inhibition of GLUT1 has been shown to reduce nasal inflammation and improve epithelial barrier function in AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.